ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO990

Evaluation of the Utility of [18F]DiFA as a Novel Kidney Hypoxia Imaging Tracer

Session Information

Category: Bioengineering and Informatics

  • 101 Bioengineering and Informatics


  • Nakata, Norihito, Nihon Medi-Physics Co., Ltd., Sodegaura, Japan
  • Kiriu, Masato, Nihon Medi-Physics Co., Ltd., Sodegaura, Japan
  • Okumura, Yuki, Nihon Medi-Physics Co., Ltd., Sodegaura, Japan
  • Matsumoto, Hiroki, Nihon Medi-Physics Co., Ltd., Sodegaura, Japan
  • Kuge, Yuji, Hokkaido University, Sapporo, Japan

It is reported that hypoxia is important as a final common pathway in which chronic kidney disease progresses to end-stage renal failure. Therefore, evaluation of hypoxic condition in the kidney is considered to be useful as a surrogate marker of drug treatment. However, it is difficult to evaluate the hypoxic condition in the kidney with the current in vitro diagnosis. We have investigated the basic properties of a new intratumoral hypoxic imaging agent 1- (2,2-Dihydroxymethyl-3- [18F] Fluoropropyl) Azomycin ([18F]DiFA) and have already reported its usefulness. In this study, we investigated whether [18F]DiFA can evaluate the hypoxic condition in the kidney using a drug-induced renal impairment model. Furthermore, comparison with existing hypoxic imaging tracer, [18F]FMISO, was also conducted.


[18F]DiFA or [18F]FMISO was administered to adriamycin-induced renal injury model rats and a PET imaging experiment was performed. Autoradiography was performed using [18F]DiFA[S1] and compared with the results of immunohistochemistry using HIF-1α as a hypoxic marker.


As a result of PET imaging of [18F]DiFA, the uptake in the kidney cortex was observed at 80 minutes after administration, and an image visualized with high contrast was presented hypoxia of the renal cortex portion (Figure.1). These analysis results were shown in the following table. Since the localization of [18F]DiFA in kidney and localization of HIF-1α were in good agreement, it was confirmed that [18F]DiFA selectively accumulated in the hypoxic region in the kidney.


These results suggested that [18F]DiFA may be useful as a hypoxia imaging tracer in the kidney compared to [18F]FMISO.


  • Commercial Support